ABSTRACT A shortcut review was carried out to establish whether intravenous glucagon is a safe and effective treatment for patients with suspected lower oesophageal food bolus impaction. Seven studies were directly relevant to the question. The author, date and country of publication, patient group studied, study type, relevant outcomes, results and study weaknesses of these papers are tabulated. The clinical bottom line is that there is no evidence for the effectiveness of glucagon in this situation. Its use may be associated with adverse effects such as vomiting, with the potential risk of oesophageal perforation. Intravenous glucagon should therefore be avoided.
CLINICAL SCENARIO
A 60-year-old man presents to the emergency department with symptoms of lower oesophageal food bolus impaction. You have previously seen intravenous glucagon used in an attempt to relieve lower oesophageal impactions but wonder if there is any evidence for its use. You wonder if there is any evidence to support use of intravenous glucagon to treat lower oesophageal food bolus impaction. 
THREE-PART QUESTION

OUTCOME
The search revealed 42 papers of which 35 were relevant to the question or of insufficient quality. The remaining seven papers are shown (see table 1).
COMMENTS
The success of glucagon in relieving food bolus impaction is seen to be variable in the studies found, ranging from 9.4% to 75%. The two studies with the higher success rates (69% and 75%) both concerned a very select patient population and excluded any patients with fixed oesophageal strictures or carcinoma of the oesophagus. It is not known whether these patients were excluded before or after trial of treatment. Of note, these studies were from the same department of the same institution, the later study being a continuation of the first. The most common range of percentage success was 32.6%-37.5%. Six of the seven studies are simple cohort studies without controls or randomisation providing a relatively low level of evidence. The highest level of evidence available is from a multicentre, prospective, double-blind randomised control trial. This showed no significant difference between patients treated with glucagon and patients given placebo. Despite being underpowered and some of the patients also being treated with diazepam, it showed responses to glucagon and placebo of 37.5% and 31.3%, respectively. These figures are very similar to the response rates in several of the other studies, which may suggest that approximately 30% of oesophageal food bolus obstructions relieve spontaneously, rather than this being the effect of glucagon. Several of the studies concluded that even though response rates were relatively low, glucagon is safe and had relatively few side effects. These conclusions are not justified by the studies, as the number of patients studied was too small to observe true effects and side effects. Given that glucagon is known to induce vomiting, this poses a potential risk of oesophageal perforation in patients with distal oesophageal impaction. Vomiting was described in two patients in two studies, and an adverse event of haematemesis and oesophageal mucosal laceration was also reported. The majority of the other studies did not report or make any reference to side effects or adverse events.
Clinical bottom line
There is no evidence to support the use of intravenous glucagon in patients with oesophageal food bolus impaction. Glucagon may induce vomiting which is undesirable in any distal oesophageal impaction due to the risk of oesophageal perforation. Patients presenting with oesophageal food bolus impaction may have undiagnosed fixed narrowing or pathology and glucagon and should therefore be avoided.
